Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623363 · ClinicalTrials.gov registry record · Phase 2
Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 7
- Study locations
NCT00623363: Completed Phase 2 study of Parkinson's Disease, sponsored by Daiichi Sankyo.
NCT00623363 is a Phase 2 study of Parkinson's Disease that has completed, run by Daiichi Sankyo. The registered enrollment target is 27 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623363, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.
Primary Outcome
Improvement in motor complications associated with Parkinson's disease are measured as "on" (good medication response); OR "on with dyskinesia" (good medication response, but with superimposed involuntary movements that interfere with activities), OR "off" (poor medication response).
Conditions Studied
Interventions
- DRUG piclozotan
- DRUG 0.9% sodium chloride (normal saline)
Study Locations (7)
Other
- Hospital Multimedica - Guatemala City
- Hospital Clinic of Neurology and Psychiatry Oradea - Oradea
California
- The Parkinson's and Movement Disorder Institute - Fountain Valley
Florida
- University of South Florida, Parkinson's Disease and Movement Disorders Center - Tampa
Georgia
- Emory University--Wesley Woods Health Center - Atlanta
New Jersey
- UMDNJ-Robert Wood Johnson Medical School - New Brunswick
New York
- Suny Downstate Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-07-13 |
| Est. Completion | 2008-07-17 |
| Phase | Phase 2 |
What the finished NCT00623363 record still lists
NCT00623363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which piclozotan is the first listed.
NCT00623363 lists 7 locations in 6 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00623363 about?
NCT00623363 is a clinical study titled "Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease". The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.
What is the current status of trial NCT00623363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2007-07-13. Estimated completion is 2008-07-17.
What conditions does trial NCT00623363 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00623363?
The interventions under investigation include: piclozotan (DRUG), 0.9% sodium chloride (normal saline) (DRUG).
Who is sponsoring clinical trial NCT00623363?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623363 being conducted?
This trial has 7 study locations across California, Florida, Georgia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00623363's enrollment target sits among peer trials
27 114th of 158 higher than 42 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI